Diamantopoulos P.T., Symeonidis A., Pappa V., Kotsianidis I., Galanopoulos A., Pontikoglou C., Anagnostopoulos A., Vassilopoulos G., Zikos P., Hatzimichael E., Papaioannou M., Megalakaki A., Repousis P., Kotsopoulou M., Dimou M., Solomou E., Dryllis G., Tsokanas D., Papoutselis M.-K., Papageorgiou S., Kyrtshonis M.-C., Kourakli A., Papadaki H., Panayiotidis P., Viniou N.-A. (2021)
The regimen of 5-azacytidine for patients with myelodysplastic syndrome (MDS) has remained unchanged since its first approval. Although several modifications have since been made and delays and dose reductions are common ...